VSTM ▲ +0.6% - Verastem, Inc. $VSTM Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers Verastem Oncology rose 0.6% following an announcement that the company will present new clinical data for VS-7375, its oral KRAS G12D inhibitor, across multiple cancer types including pancreatic, lung, and colorectal cancers. The data presentation highlights the drug candidate's potential as a best-in-class therapy, which could support investor confidence in the company's clinical pipeline. 08-SEP-2026 07:30 AM ET